MyFinsight
Home
Blog
About
Inventory
$22,625,945
(31.48%↑ Y/Y)
Cash and cash
equivalents
$16,563,705
(14788922.32%↑ Y/Y)
Prepaid expenses
$2,831,280
(157.39%↑ Y/Y)
Accounts receivable, net
of allowances
$686,235
In-process research and
development, net of...
$69,385,938
(-5.47%↓ Y/Y)
Total current assets
$42,707,165
(133.26%↑ Y/Y)
Total assets
$112,093,103
(22.23%↑ Y/Y)
Total liabilities and
stockholders equity
$112,093,103
(22.23%↑ Y/Y)
Total liabilities
$71,708,109
(20.90%↑ Y/Y)
Total stockholders
equity
$40,384,994
(24.65%↑ Y/Y)
Accumulated deficit
-$105,107,566
(-78.02%↓ Y/Y)
Total current
liabilities
$58,787,194
(10.94%↑ Y/Y)
Notes payable, net of
deferred financing costs
$6,410,161
Note payable to
related party
$3,800,111
Deferred tax liability
$2,710,643
(7.53%↑ Y/Y)
Additional paid-in capital
$145,481,984
(59.11%↑ Y/Y)
Common stock - 0.0001
par value...
$10,576
(47.81%↑ Y/Y)
Accrued expenses
$25,836,120
(205.44%↑ Y/Y)
License payable
$15,650,000
(-44.89%↓ Y/Y)
Due to related party
$9,985,558
(33.78%↑ Y/Y)
Accounts payable
$7,315,516
(-15.60%↓ Y/Y)
Back
Back
Balance Sheet
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)
source: myfinsight.com